{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-280240","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.069666+00:00","generated_at":"2026-06-07T23:18:45.424235+00:00","sec_items":["1.01","2.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zevra completes Acer acquisition; issues stock, CVRs, and $6M registered direct offering","bullets":["Acquisition of Acer closed Nov 17; Acer shareholders receive 0.1210 Zevra shares + one CVR per share.","CVRs entitle holders to up to $76M upon achieving OLPRUVA net sales milestones ($35M-$200M) and regulatory approvals.","Zevra raised ~$6M via registered direct offering of 1,382,489 shares + warrants at $4.34/unit; also issued 917,934 shares to cancel Acer warrant.","Prior to merger, Zevra purchased Acer senior secured debt for $28.5M in cash, stock, and notes.","OLPRUVA (FDA-approved for UCDs) adds commercial-stage asset; EDSIVO for vEDS in Phase 3."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-280240","json":"https://secwatch.observer/filing/0001193125-23-280240.json","markdown":"https://secwatch.observer/filing/0001193125-23-280240.md","text":"https://secwatch.observer/filing/0001193125-23-280240.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523280240/0001193125-23-280240-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523280240/d209243d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:18:45.424235+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16f30c32397af6b3d2b71ca656151bea44efe3c4","claim":"ZEVRA THERAPEUTICS, INC. completed an acquisition involving Acer Therapeutics Inc. for 0.1210 validly issued, fully paid and non-assessable shares of Zevra common stock, $0.0001 par value per share, and one CVR (closed 2023-11-17).","evidence_excerpt":"Completion of Acquisition or Disposition of Assets On November 17, 2023 (the “ Closing Date ”), Zevra completed the previously announced acquisition of Acer Therapeutics Inc., a Delaware corporation (“ Acer ”), pursuant to the Agreement and Plan of Merger (the “ Merger Agreement ”), dated August 30, 2023, by and among Zevra, Aspen Z Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Zevra (“ Merger Sub ”), and Acer.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000119312523280240/0001193125-23-280240-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Acer Therapeutics Inc."},{"label":"Consideration","value":"0.1210 validly issued, fully paid and non-assessable shares of Zevra common stock, $0.0001 par value per share, and one CVR"},{"label":"Closing","value":"2023-11-17"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}